The 28th BioJapan closed on October 9 at Pacifico Yokohama · At Booth C-65, GPCR reporter cells, immuno-oncology cell models and cell line development, with posters and catalogs in Japanese

October 28, 2026 · Shanghai

Shanghai, October 28, 2026 — The 28th BioJapan closed on October 9 at Pacifico Yokohama. Reqbio Bioscience exhibited at Booth C-65 and held one-on-one meetings with Japanese and international clients booked in advance. BioJapan 2026 ran alongside Regenerative Medicine JAPAN 2026 and healthTECH JAPAN 2026, and was the company’s first overseas exhibition since it achieved ISO 9001:2015 certification.

First held in 1986, BioJapan is the world’s longest-running event dedicated to biotechnology. According to figures published by the organizer for the previous edition, the 2025 shows together drew 1,568 companies and 3,073 participants from 39 countries and regions, with 25,498 partnering meetings held. On the exhibition side, 1,134 companies occupied 917 booths and welcomed 22,167 visitors. Complete figures for the 2026 edition have not yet been released.

Across the three days, the Reqbio booth was built around two lines: drug target cell models and technical services. On the product side, the portfolio spans GPCR reporter cell lines, immuno-oncology (IO) cell models, other stable cell lines and companion assay kits. The GPCR range covers Gα15 / Gα16 coupling, β-arrestin recruitment, and CRE-Luc and NFAT-Luc reporter readouts, alongside multiplex models such as the GLP1R&GCGR&GIPR triple reporter and GLP1R&GIPR dual reporter lines. The IO range includes THP-1 reporter cells, STING and cGAS knockout and point-mutation knock-in models, and NFκB-SEAP and ISRE-Luc reporter systems.

On the service side, the offering covers stable cell line development (overexpression, knockdown, knockout, knock-in), the development, optimization, validation and transfer of GPCR cell-based assays, kinase screening platforms, PROTAC degradation models, ADC target cell models, molecular biology and gene editing, and drug safety and toxicology evaluation. The booth back wall carried five Japanese-language posters covering technical advantages, immuno-oncology cell models, GPCR cell models and the service overview, and Japanese-language versions of the service sheet and of the GPCR and IO catalogs were distributed on site, so visitors could match a target to a readout format and settle on a model without working through a language barrier.

Japan, the company added, has a dense pipeline in GPCR-targeted small molecules, ADCs, immuno-oncology and targeted protein degradation — areas that overlap closely with its own portfolio. Over the three days, Reqbio held detailed discussions with a number of Japanese and international organizations on reporter cell line construction timelines, assay window and Z′ factor quality metrics, cell bank records and licensing scope. Its commonly used host cell lines — Jurkat E6.1, CHO-K1, HEK293, Raji and THP-1 — are all commercially licensed, supporting downstream genetic modification, model development and commercial resale, backed by complete cell bank records and a cell line authentication workflow (STR profiling, NGS-based authentication, mycoplasma and adventitious agent testing).

Following the show, Reqbio will work through the enquiries received at the booth one by one, by target and readout format, providing model selection advice and supporting technical documentation. The company said it will continue to take part in BioJapan and to further strengthen local-language materials and technical support responsiveness for overseas markets.

About Reqbio

Reqbio Bioscience specializes in the construction and validation of drug target cell models. Its products include GPCR reporter cells, immuno-oncology cell models, other stable cell lines and assay kits; its technical services cover stable cell line development, GPCR cell-based assays, kinase screening platforms, PROTAC degradation models, ADC target cell models, molecular biology and gene editing, and drug safety and toxicology. The company is certified to ISO 9001:2015. Its commonly used host cell lines Jurkat E6.1, CHO-K1, HEK293, Raji and THP-1 are commercially licensed, enabling genetic modification, model development and commercial resale, and are supported by complete cell bank records and cell line authentication (STR, NGS, mycoplasma, adventitious agents).

Media Contact